Supernus Pharmaceuticals Inc(SUPN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:11 AM ET (Korea 9/11 17:11)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.91 | Insider Own | 6.38% | Shs Outstand | 58.2M | Perf Week | -5.31% |
| Market Cap | 2.42B | Forward P/E | 9.35 | EPS next Y | 73.88% | Insider Trans | -4.09% | Shs Float | 54.4M | Perf Month | -11.07% |
| Enterprise Value | 2.09B | PEG | 0.5 | EPS next Q | 0.61 | Inst Own | 102.94% | Short Float | 7.62% | Perf Quarter | -7.54% |
| Income | -0.11B | P/S | 2.92 | EPS this Y | -20.71% | Inst Trans | 1.78% | Short Ratio | 4.92 | Perf Half Y | -21.66% |
| Sales | 0.83B | P/B | 2.35 | EPS next 5Y | 18.63% | ROA | -7.82% | Short Interest | 4.15M | Perf YTD | -16.12% |
| Book/sh | 17.73 | P/C | 6.51 | EPS past 3/5Y | - | ROE | -10.49% | 52W High | -30.14% ($59.68) | Perf Year | -9.78% |
| Cash/sh | 6.4 | P/FCF | 128.97 | Sales past 3/5Y | 2.52% 6.68% | ROIC | -10.36% | 52W Low | 0.46% ($41.50) | Perf 3Y | 36.29% |
| Dividend Est. | - | EV/EBITDA | 55.74 | EPS Y/Y TTM | -264.42% | Gross Margin | 75.83% | Volatility(W/M) | 2.7% 2.94% | Perf 5Y | 56.79% |
| Dividend TTM | - | EV/Sales | 2.52 | Sales Y/Y TTM | 24.85% | Oper. Margin | -7.73% | ATR (14) | 1.48 | Perf 10Y | 92.12% |
| Dividend Ex-Date | - | Quick Ratio | 1.84 | EPS Q/Q | -353.07% | Profit Margin | -13.23% | RSI (14) | 31.03 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | Sales Q/Q | 32.4% | SMA20 | -7.71% ($45.17) | Beta | 0.56 | Target Price | $61.75 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/3 | SMA50 | -10.12% ($46.38) | Rel Volume | 0.86 | Prev Close | $42.07 |
| Employees | 778 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 24.52% 6.7% | SMA200 | -13.96% ($48.45) | Avg Volume(3M) | 0.84M | Price | $41.69 |
| IPO | 2012/5/1 | Option/Short | Yes/Yes | Trades | 8768 | Volume | 721,945 | Change | -0.9% |
Company
SUPN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US specialty pharmaceutical company that develops and sells therapeutics for the central nervous system. It develops and commercializes treatments for central nervous system disorders such as epilepsy, attention deficit disorders, and Parkinson's disease, with exposure to product revenue and a drug development pipeline. The company operates in the central nervous system specialty pharmaceuticals sector.
Over the past 1 year, on the lower side
30% below its 1-year high.
SUPN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -20.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +36.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 102.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSIL 0.03%
IBRN 0.03%
PJP 0.03%
ASD 0.03%
XPH 0.02%It ranks #4 in the industry
Based on market cap of $2B.
SUPN $2B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is SUPN?
SUPN belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SUPN?
The market cap of SUPN is approximately $2.4B, ranking 1,949 within its sector.
What is the 52-week high and low for SUPN?
SUPN has recorded a 52-week high of $59.68 and a low of $41.50.
